Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy

NCT02780687 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Neoplasms

Interventions

DRUG: Afatinib

Sponsor

Boehringer Ingelheim